Clinical Trial Update: Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster [Phase 3]

View source ↗

Summary

Phase 3 safety and immunogenicity study of GlaxoSmithKline's herpes zoster subunit vaccine (HZ/su) given in a two-dose schedule to adults aged 50 and older with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Shingrix (recombinant zoster vaccine, adjuvanted)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Zoster | Phase 3 | Status: COMPLETED | Results posted: 2025-03-30